TY - JOUR T1 - ARE GEOGRAPHIC FACTORS ASSOCIATED WITH POORER OUTCOMES IN PATIENTS DIAGNOSED WITH COVID-19? JF - medRxiv DO - 10.1101/2021.01.25.21250404 SP - 2021.01.25.21250404 AU - Rosa Magallón-Botaya AU - Bárbara Oliván-Blázquez AU - Karen Lizzette Ramirez-Cervantes AU - Fatima Mendez-Lopez de la Mazanara AU - Marc Casajuana-Closas AU - Eva Esteban-Andrés Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/26/2021.01.25.21250404.abstract N2 - Background The prognosis of patients with COVID-19, with older age and comorbidities, is associated with a more severe course and higher fatality rates but no analysis has yet included factors related to the geographical area/municipality in which the affected patients live. So the objective of this study is to analyse the prognosis of patients with COVID-19 in terms of sex, age, comorbidities, and geographic variables.Methods A retrospective cohort of 6286 patients diagnosed with COVID-19 was analysed, considering demographic data, previous comorbidities and geographic variables. The main study variables were hospital admission, Intensive Care Unit (ICU) admission and death due to worsening symptoms; and the secondary variables were sex, age, comorbidities and geographic variables (size of the area of residence, distance to the hospital and the driving time to the hospital). A comparison analysis and a multivariate Cox model were performed.Results The multivariate Cox model showed that women had a better prognosis in any type of analysed prognosis. Most of the comorbidities studied were related to a poorer prognosis except for dementia, which is related to lower admissions and higher mortality. Suburban areas were associated with greater mortality and with less hospital or ICU admission. Distance to the hospital was also associated with hospital admission.Conclusions Factors such as type of municipality and distance to hospital act as social health determinants. This fact must be taken account in order to stablish specifics prevention measures and treatment protocols.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support for the conduct of the research was obtained from the Health Institute Carlos III (ISCIII) (grants number COV20_00634 and COV20_00519), and from de Institute of Research IIS-AragonAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Clinical Research Ethics Committee of Aragon: PI20/262All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAragon Health Service Institute of Research IIS-Aragon ER -